4.5 Article

Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real-world Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Journal

JOURNAL OF RHEUMATOLOGY
Volume 48, Issue 3, Pages 367-375

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.191117

Keywords

epidemiology; psoriatic arthritis; quality of life; registries

Categories

Funding

  1. Corrona, LLC
  2. Novartis
  3. Amgen
  4. Boehringer Ingelheim
  5. Bristol Myers Squibb
  6. Celgene
  7. Crescendo
  8. Eli Lilly and Company
  9. Genentech
  10. Gilead
  11. GSK
  12. Janssen
  13. Merck
  14. Momenta Pharmaceuticals
  15. Ortho Dermatologics
  16. Pfizer Inc.
  17. Regeneron
  18. Roche
  19. Sun
  20. UCB
  21. AbbVie

Ask authors/readers for more resources

The study revealed that patients with clinical enthesitis had worse disease activity regardless of the location of enthesitis in psoriatic arthritis. Patients with enthesitis in lower or both upper and lower sites experienced more severe pain, fatigue, and work impairment.
Objective. To assess the effect of clinical enthesitis by body site in patients with psoriatic arthritis (PsA). Methods. Adults with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry (March 2013-March 2018) were included. Enthesitis at enrollment was assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index and classified by affected sites (upper, lower, or both). Disease activity (e.g., Clinical Disease Activity Index, Clinical Disease Activity Index for PsA), patient-reported outcomes (PRO; e.g., patient-reported pain and Fatigue), and work productivity were compared between those with and without enthesitis using t- or Wilcoxon rank-sum tests for continuous variables and chi-square or Fisher exact tests for categorical variables. The association of enthesitis with disease activity and PRO measures versus no enthesitis was modeled using multivariable-adjusted linear or logistic regression. Results. Of 2003 patients with PsA, 391 (19.5%) had enthesitis: 80 (20.5%) in upper sites only; 137 (35.0%) in lower sites only; and 174 (44.5%) in both. Regardless of location, disease activity and PRO were worse in patients with versus without enthesitis. In adjusted models, the presence of enthesitis at any site was significandy associated with worse disease activity versus no enthesitis. Enthesitis in lower or both upper and lower sites was associated with higher pain and fatigue scores and greater work impairment versus no enthesitis. Conclusion. Patients with clinical enthesitis had worse disease activity regardless of enthesitis location versus those without enthesitis, and patients with enthesitis in lower or both upper and lower sites had worse pain, fatigue, and work impairment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available